我国药品价格谈判机制中引入卫生技术评估的动阻力研究  

Research on the Dynamic Resistance of Introducing Health Technology Evaluation in Pharmaceutical Pricing Negotiation Mechanism of China

作　　者：施文凯 吕兰婷 

机构地区：[1]中国人民大学公共管理学院,北京100872

出　　处：《中国卫生经济》2016年第8期78-81,共4页Chinese Health Economics

基　　金：中国人民大学科学研究基金(中央高校基本科研业务费专项资金资助)项目(15XNQ005)

摘　　要：目的:为完善我国药品价格谈判机制提供政策建议。方法:主要通过基于Leavitt模型的动阻力因素分析,并综合运用文献法和比较研究法,尝试研究将HTA引入我国药价谈判机制的动阻力以及引入路径。结果:动力主要来自于决策方与药企的现实要求,目前构建药价谈判机制提供的契机等;阻力主要包括HTA基础薄弱,决策方对HTA认识与支持不足等。结论:建议相关部门机构把握当前药价改革的政策窗口期,在药价谈判机制中将HTA作为关键一环嵌入设计,并以此为切入点扩大对HTA的利用,逐渐推开循证决策的理念。Objective： To provide policy recommendations on the pharmaceutical pricing negotiation mechanism in China. Meth- ods： Based on analyzing the dynamic resistance factors of Leavitt model, literature, review and comparative research were comprehen- sively applied to introduce health technology assessment （HTA） into the dynamic resistance of pharmaceutical pricing negotiation mechanism in China and analyze the path. Results： The driving forces came from the realistic request of decision makers and phar- maceutical companies and the opportunities provided by constructing pharmaceutical pricing negotiation mechanism. The restraining forces included weak capacity of HTA; low recognition of HTA. Conclusion： It suggested that relavant deparments should seize the current policy ＂window＂ of pharmaceutical pricing reform, introduce HTA as an important link into the design of pharmaceutical pricing negotiation, use it as a breakthrough point to introduce broader use and gradually promote the concept of evidence-based de- cision-making.

关 键 词：药品价格改革 谈判机制 卫生技术评估 动力 阻力 

分 类 号：R95[医药卫生—药学]